Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
- Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) has voluntarily paused the AROENaC1001 Phase 1/2 study evaluating ARO-ENaC for cystic fibrosis.
- ARO-ENaC is the company's investigational RNA interference (RNAi) therapeutic.
- The decision comes after receiving a preliminary update from an ongoing chronic toxicology study in rats that showed unexpected signals of local lung inflammation.
- The company has instructed investigators to pause new screening, enrollment, and any further dosing pending additional data from the ongoing chronic rat toxicology study and another ongoing chronic primate toxicology study.
- Price Action: ARWR shares are down 26.7% at $62.25 during the premarket session on the last check Friday.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!